Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia
Open Access
- 4 May 2017
- journal article
- Published by American Society of Hematology in Blood
- Vol. 129 (18), 2587-2591
- https://doi.org/10.1182/blood-2016-11-751008
Abstract
To the editor: Acute myeloid leukemia (AML) is an aggressive malignancy with a variety of genetic and epigenetic aberrations pinpointing a multistep process of leukemogenesis.[1][1] It is hierarchically organized, with bulk leukemic cells derived from leukemia-initiating cells that possess self-Keywords
This publication has 22 references indexed in Scilit:
- Acute myeloid leukemia with TP53 germ line mutationsBlood, 2016
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaNew England Journal of Medicine, 2016
- TP53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantationBritish Journal of Haematology, 2016
- Identification of pre-leukaemic haematopoietic stem cells in acute leukaemiaNature, 2014
- Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remissionProceedings of the National Academy of Sciences, 2014
- A novel hierarchical prognostic model of AML solely based on molecular mutationsBlood, 2012
- Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid LeukemiaScience Translational Medicine, 2012
- Germline mutations in the DNA damage response genesBRCA1,BRCA2,BARD1andTP53in patients with therapy related myeloid neoplasmsJournal of Medical Genetics, 2012
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcomeBlood, 2012
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997